British Thoracic Society Standards of Care Committee. BTS statement on malignant mesothelioma in the UK, 2007. Thorax. 2007;62(Suppl 2):ii1–19.
Google Scholar
Scherpereel A, Astoul P, Baas P, et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J. 2010;35:479–95.
Article
CAS
Google Scholar
Yates DH, Corrin B, Stidolph PN, et al. Malignant mesothelioma in south east England: clinicopathological experience of 272 cases. Thorax. 1997;52:507–12.
Article
CAS
Google Scholar
Howel D, Arblaster L, Swinburne L, et al. Routes of asbestos exposure and the development of mesothelioma in an English region. Occup Environ Med. 1997;54:403–9.
Article
CAS
Google Scholar
Sekido Y. Molecular pathogenesis of malignant mesothelioma. Carcinogenesis. 2013;34:1413–9.
Article
CAS
Google Scholar
Beckett P, Edwards J, Fennell D, et al. Demographics, management and survival of patients with malignant pleural mesothelioma in the National Lung Cancer Audit in England and Wales. Lung Cancer. 2015;88:344–8.
Article
CAS
Google Scholar
Park EK, Takahashi K, Hoshuyama T, et al. Global magnitude of reported and unreported mesothelioma. Environ Health Perspect. 2011;119:514–8.
Article
Google Scholar
Robinson BM. Malignant pleural mesothelioma: an epidemiological perspective. Ann Cardiothorac Surg. 2012;1:491–6.
Google Scholar
Bibby AC, Tsim S, Kanellakis N, et al. Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment. Eur Respir Rev. 2016;25:472–86.
Article
Google Scholar
Barrett JC, Lamb PW, Wiseman RW. Multiple mechanisms for the carcinogenic effects of asbestos and other mineral fibers. Environ Health Perspect. 1989;81:81–9.
Article
CAS
Google Scholar
Edwards JG, Faux SP, Plummer SM, et al. Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma. Clin Cancer Res. 2002;8:1857–62.
CAS
Google Scholar
Vane JR, Mitchell JA, Appleton I, et al. Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation. Proc Natl Acad Sci U S A. 1994;91:2046–50.
Article
CAS
Google Scholar
Seibert K, Zhang Y, Leahy K, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci U S A. 1994;91:12013–7.
Article
CAS
Google Scholar
Nakanishi M, Rosenberg DW. Multifaceted roles of PGE2 in inflammation and cancer. Semin Immunopathol. 2013;35:123–37.
Article
CAS
Google Scholar
Zappavigna S, Cossu AM, Grimaldi A, et al. Anti-Inflammatory drugs as anticancer agents. Int J Mol Sci. 2020;21:2605. https://doi.org/10.3390/ijms21072605.
Article
CAS
Google Scholar
Li S, Jiang M, Wang L, et al. Combined chemotherapy with cyclooxygenase-2 (COX-2) inhibitors in treating human cancers: Recent advancement. Biomed Pharmacother. 2020;129:110389.
Article
CAS
Google Scholar
Stoppoloni D, Canino C, Cardillo I, et al. Synergistic effect of gefitinib and rofecoxib in mesothelioma cells. Mol Cancer. 2010;9:27. https://doi.org/10.1186/1476-4598-9-27.
Article
CAS
Google Scholar
O’Kane SL, Eagle GL, Greenman J, et al. COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines. Lung Cancer. 2010;67:160–5.
Article
Google Scholar
Yin W, Zheng G, Su S, et al. The Value of COX-2, NF-κB, and Blood Routine Indexes in the Prognosis of Malignant Peritoneal Mesothelioma. Oncol Res Trehat. 2019;42:334–41.
Article
CAS
Google Scholar
Dixon DA, Kaplan CD, McIntyre TM, et al. Post-transcriptional control of cyclooxygenase-2 gene expression. The role of the 3’-untranslated region. J Biol Chem. 2000;275:11750–7.
Article
CAS
Google Scholar
Sengupta S, Jang BC, Wu MT, et al. The RNA-binding protein HuR regulates the expression of cyclooxygenase-2. J Biol Chem. 2003;278:25227–33.
Article
CAS
Google Scholar
Stoppoloni D, Cardillo I, Verdina A, et al. Expression of the embryonic lethal abnormal vision-like protein HuR in human mesothelioma: association with cyclooxygenase-2 and prognosis. Cancer. 2008;113:2761–9.
Article
CAS
Google Scholar
Finetti F, Travelli C, Ercoli J, et al. Prostaglandin E2 and Cancer: insight into tumor progression and immunity. Biology (Basel). 2020;9:434. https://doi.org/10.3390/biology9120434.
Article
CAS
Google Scholar
O’Callaghan G, Houston A. Prostaglandin E2 and the EP receptors in malignancy: possible therapeutic targets? Br J Pharmacol. 2015;172:5239–50.
Article
Google Scholar
Xu S, Zhou W, Ge J, et al. Prostaglandin E2 receptor EP4 is involved in the cell growth and invasion of prostate cancer via the cAMP PKA/PI3K Akt signaling pathway. Mol Med Rep. 2018;17:4702–12.
CAS
Google Scholar
Donnini S, Finetti F, Solito R, et al. EP2 prostanoid receptor promotes squamous cell carcinoma growth through epidermal growth factor receptor transactivation and iNOS and ERK1/2 pathways. FASEB J. 2007;21:2418–30.
Article
CAS
Google Scholar
Shukla A, Barrett TF, MacPherson MB, et al. An extracellular signal-regulated kinase 2 survival pathway mediates resistance of human mesothelioma cells to asbestos-induced injury. Am J Respir Cell Mol Biol. 2011;45:906–14.
Article
CAS
Google Scholar
Cacciotti P, Barbone D, Porta C, et al. SV40-dependent AKT activity drives mesothelial cell transformation after asbestos exposure. Cancer Res. 2005;65:5256–62.
Article
CAS
Google Scholar
Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev. 1999;79:1193–226.
Article
CAS
Google Scholar
Subbaramaiah K, Dannenberg AJ. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci. 2003;24:96–102.
Article
CAS
Google Scholar
Straub RH. The complex role of estrogens in inflammation. Endocr Rev. 2007;28:521–74.
Article
CAS
Google Scholar
Brown SB, Hankinson SE. Endogenous estrogens and the risk of breast, endometrial, and ovarian cancers. Steroids. 2015;99:8–10.
Article
CAS
Google Scholar
Huang Q, Zhang Z, Liao Y, et al. 17β-estradiol upregulates IL6 expression through the ERβ pathway to promote lung adenocarcinoma progression. J Exp Clin Cancer Res 2018; 37: 133–018-0804-5.
Stoppoloni D, Salvatori L, Biroccio A, et al. Aromatase inhibitor exemestane has antiproliferative effects on human mesothelioma cells. J Thorac Oncol. 2011;6:583–91.
Article
Google Scholar
Nuvoli B, Germoni S, Morosetti C, et al. Exemestane blocks mesothelioma growth through downregulation of cAMP, pCREB and CD44 implicating new treatment option in patients affected by this disease. Mol Cancer. 2014;13:69–4598.
Article
Google Scholar
Nuvoli B, Sacconi A, Cortese G, et al. Reduction of estradiol in human malignant pleural mesothelioma tissues may prevent tumour growth, as implied by in in-vivo and in-vitro models. Oncotarget. 2016;7:47116–26.
Article
Google Scholar
Nuvoli B, Galati R. Cyclooxygenase-2, epidermal growth factor receptor, and aromatase signaling in inflammation and mesothelioma. Mol Cancer Ther. 2013;12:844–52.
Article
CAS
Google Scholar
Martey CA, Pollock SJ, Turner CK, et al. Cigarette smoke induces cyclooxygenase-2 and microsomal prostaglandin E2 synthase in human lung fibroblasts: implications for lung inflammation and cancer. Am J Physiol Lung Cell Mol Physiol. 2004;287:L981-91.
Article
Google Scholar
Subbaramaiah K, Morris PG, Zhou XK, et al. Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. Cancer Discov. 2012;2:356–65.
Article
CAS
Google Scholar
Micallef D, Micallef S, Schembri-Wismayer P, et al. Novel applications of COX-2 inhibitors, metformin, and statins for the primary chemoprevention of breast cancer. J Turk Ger Gynecol Assoc. 2016;17:214–23.
Article
CAS
Google Scholar
Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27–55.
Article
CAS
Google Scholar
Elzoghby AO, Mostafa SK, Helmy MW, et al. Superiority of aromatase inhibitor and cyclooxygenase-2 inhibitor combined delivery: Hyaluronate-targeted versus PEGylated protamine nanocapsules for breast cancer therapy. Int J Pharm. 2017;529:178–92.
Article
CAS
Google Scholar
Stabile LP, Farooqui M, Kanterewicz B, et al. Preclinical Evidence for Combined Use of Aromatase Inhibitors and NSAIDs as Preventive Agents of Tobacco-Induced Lung Cancer. J Thorac Oncol. 2018;13:399–412.
Article
CAS
Google Scholar
Falandry C, Canney PA, Freyer G, et al. Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer. Ann Oncol. 2009;20:615–20.
Article
CAS
Google Scholar
Denicourt C, Dowdy SF. Cip/Kip proteins: more than just CDKs inhibitors. Genes Dev. 2004;18:851–5.
Article
CAS
Google Scholar
Karimian A, Ahmadi Y, Yousefi B. Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage. DNA Repair. 2016;42:63–71.
Article
CAS
Google Scholar
Lin CP, Lin CS, Lin HH, et al. Bergapten induces G1 arrest and pro-apoptotic cascade in colorectal cancer cells associating with p53/p21/PTEN axis. Environ Toxicol. 2019;34:303–11.
Article
CAS
Google Scholar
Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13:1501–12.
Article
CAS
Google Scholar
Charrier-Savournin FB, Château MT, Gire V, et al. p21-Mediated nuclear retention of cyclin B1-Cdk1 in response to genotoxic stress. Mol Biol Cell. 2004;15:3965–76.
Article
CAS
Google Scholar
Baldi A, Piccolo MT, Boccellino MR, et al. Apoptosis induced by piroxicam plus cisplatin combined treatment is triggered by p21 in mesothelioma. PLoS One. 2011;6:e23569.
Article
CAS
Google Scholar
Nuvoli B, Santoro R, Catalani S, et al. CELLFOODTM induces apoptosis in human mesothelioma and colorectal cancer cells by modulating p53, c-myc and pAkt signaling pathways. J Exp Clin Cancer Res. 2014;33:24. https://doi.org/10.1186/1756-9966-33-24.
Nuvoli B, Camera E, Mastrofrancesco A, et al. Modulation of reactive oxygen species via ERK and STAT3 dependent signalling are involved in the response of mesothelioma cells to exemestane. Free Radic Biol Med. 2018;115:266–77.
Article
CAS
Google Scholar
Ghosh R, Alajbegovic A. Gomes AV NSAIDs and cardiovascular diseases: role of reactive oxygen species. Oxid Med Cell Longev. 2015;2015:536962.
Article
Google Scholar
Russo T, Zambrano N, Esposito F, et al. A p53-independent pathway for activation of WAF1/CIP1 expression following oxidative stress. J Biol Chem. 1995;270:29386–91.
Article
CAS
Google Scholar
Dabiri Y, Abu El Maaty MA, Chan HY, et al. p53-Dependent Anti-Proliferative and Pro-Apoptotic Effects of a Gold(I) N-Heterocyclic Carbene (NHC) Complex in Colorectal Cancer Cells. Front Oncol. 2019;9:438.
Article
Google Scholar
Hoxhaj G, Manning BD. The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. Nat Rev Cancer. 2020;20:74–88.
Article
CAS
Google Scholar
Rossini M, Rizzo P, Bononi I, et al. New perspectives on diagnosis and therapy of malignant pleural mesothelioma. Front Oncol. 2018;8:91.
Article
Google Scholar
Mikami I, Zhang F, Hirata T, et al. Inhibition of activated phosphatidylinositol 3-kinase/AKT pathway in malignant pleural mesothelioma leads to G1 cell cycle arrest. Oncol Rep. 2010;24:1677–81.
CAS
Google Scholar
Yamaji M, Ota A, Wahiduzzaman M, et al. Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells. Cancer Med. 2017;6:2646–59.
Article
CAS
Google Scholar
Le Gall M, Chambard JC, Breittmayer JP, et al. The p42/p44 MAP kinase pathway prevents apoptosis induced by anchorage and serum removal. Mol Biol Cell. 2000;11:1103–12.
Article
Google Scholar
Zhuang S, Schnellmann RG. A death-promoting role for extracellular signal-regulated kinase. J Pharmacol Exp Ther. 2006;319:991–7.
Article
CAS
Google Scholar
Zhuang S, Yan Y, Daubert RA, et al. ERK promotes hydrogen peroxide-induced apoptosis through caspase-3 activation and inhibition of Akt in renal epithelial cells. Am J Physiol Renal Physiol. 2007;292:F440-7.
Article
Google Scholar
Yang J, Wang X, Gao Y, et al. Inhibition of PI3K-AKT Signaling Blocks PGE(2)-Induced COX-2 Expression in Lung Adenocarcinoma. Onco Targets Ther. 2020;13:8197–208.
Article
CAS
Google Scholar
St-Germain ME, Gagnon V, Mathieu I, et al. Akt regulates COX-2 mRNA and protein expression in mutated-PTEN human endometrial cancer cells. Int J Oncol. 2004;24:1311–24.
CAS
Google Scholar
Choi EM, Kwak SJ, Kim YM, et al. COX-2 inhibits anoikis by activation of the PI-3K/Akt pathway in human bladder cancer cells. Exp Mol Med. 2005;37:199–203.
Article
CAS
Google Scholar
Deng QF, Fang QY, Ji XX, et al. Cyclooxygenase-2 mediates gefitinib resistance in non-small cell lung cancer through the EGFR/PI3K/AKT axis. J Cancer. 2020;11:3667–74.
Article
CAS
Google Scholar
Glynn SA, Prueitt RL, Ridnour LA, et al. COX-2 activation is associated with Akt phosphorylation and poor survival in ER-negative, HER2-positive breast cancer. BMC Cancer. 2010;10:626. https://doi.org/10.1186/1471-2407-10-626.
Article
Google Scholar
Ferreira LP, Gaspar VM, Mano JF. Design of spherically structured 3D in vitro tumor models -Advances and prospects. Acta Biomater. 2018;75:11–34.
Article
CAS
Google Scholar
Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 1987;8:138–40.
CAS
Google Scholar
Liu R, Chen Y, Liu G, et al. PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers. Cell Death Dis. 2020;11:797. https://doi.org/10.1038/s41419-020-02998-6.
Article
CAS
Google Scholar